276 related articles for article (PubMed ID: 30431588)
1. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.
Ahn YH; Kim SH; Han KH; Choi HJ; Cho H; Lee JW; Shin JI; Cho MH; Lee JH; Park YS; Ha IS; Cheong HI; Kim SY; Lee SJ; Kang HG
Medicine (Baltimore); 2018 Nov; 97(46):e13157. PubMed ID: 30431588
[TBL] [Abstract][Full Text] [Related]
2. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
[TBL] [Abstract][Full Text] [Related]
3. Cost analysis on the use of rituximab and calcineurin inhibitors in children and adolescents with steroid-dependent nephrotic syndrome.
Iorember F; Aviles D; Kallash M; Bamgbola O
Pediatr Nephrol; 2018 Feb; 33(2):261-267. PubMed ID: 28864927
[TBL] [Abstract][Full Text] [Related]
4. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
Ravani P; Bonanni A; Ghiggeri GM
BMJ Open; 2017 Mar; 7(3):e013319. PubMed ID: 28314744
[TBL] [Abstract][Full Text] [Related]
5. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.
Van Horebeek I; Knops N; Van Dyck M; Levtchenko E; Mekahli D
Acta Clin Belg; 2017 Jun; 72(3):147-155. PubMed ID: 27409338
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
Huang J; Du J; Wang S; Xiao L; Zhao X
Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
[TBL] [Abstract][Full Text] [Related]
8. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome.
Basu B; Preussler S; Sander A; Mahapatra TKS; Schaefer F
BMC Nephrol; 2020 Nov; 21(1):520. PubMed ID: 33256621
[TBL] [Abstract][Full Text] [Related]
10. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.
Ravani P; Magnasco A; Edefonti A; Murer L; Rossi R; Ghio L; Benetti E; Scozzola F; Pasini A; Dallera N; Sica F; Belingheri M; Scolari F; Ghiggeri GM
Clin J Am Soc Nephrol; 2011 Jun; 6(6):1308-15. PubMed ID: 21566104
[TBL] [Abstract][Full Text] [Related]
11. Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study.
Takahashi T; Okamoto T; Sato Y; Yamazaki T; Hayashi A; Aoyagi H; Ueno M; Kobayashi N; Uetake K; Nakanishi M; Ariga T
Pediatr Nephrol; 2019 Jan; 34(1):87-96. PubMed ID: 30141179
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
Guitard J; Hebral AL; Fakhouri F; Joly D; Daugas E; Rivalan J; Guigonis V; Ducret F; Presne C; Pirson Y; Hourmant M; Glachant JC; Vendrely B; Moranne O; Faguer S; Chauveau D
Nephrol Dial Transplant; 2014 Nov; 29(11):2084-91. PubMed ID: 24920841
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in The Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review.
Jellouli M; Charfi R; Maalej B; Mahfoud A; Trabelsi S; Gargah T
J Pediatr; 2018 Jun; 197():191-197.e1. PubMed ID: 29680473
[TBL] [Abstract][Full Text] [Related]
14. Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects.
Sinha A; Mathew G; Arushi A; Govindarajan S; Ghanapriya K; Grewal N; Rai K; Brijwal M; Kalluru SL; Tewari P; Misra A; Khandelwal P; Hari P; Bagga A
Nephrol Dial Transplant; 2023 Mar; 38(4):939-949. PubMed ID: 36071552
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of rituximab therapy against intractable steroid-resistant nephrotic syndrome.
Nakagawa T; Shiratori A; Kawaba Y; Kanda K; Tanaka R
Pediatr Int; 2016 Oct; 58(10):1003-1008. PubMed ID: 26865241
[TBL] [Abstract][Full Text] [Related]
16. Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy.
Ramachandran R; Bharati J; Rao I; Kashif AW; Nada R; Minz R; Gupta KL; Kohli HS
Nephrology (Carlton); 2019 Dec; 24(12):1241-1247. PubMed ID: 30586217
[TBL] [Abstract][Full Text] [Related]
17. Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab.
Fujimoto K; Kagaya Y; Kumano S; Fujii A; Tsuruyama Y; Matsuura T; Yamazaki K; Nomura K; Okada K; Okino K; Adachi H; Furuichi K; Yokoyama H
Clin Nephrol; 2021 Jan; 95(1):29-36. PubMed ID: 33074094
[TBL] [Abstract][Full Text] [Related]
18. Protocol for an open-label, single-arm, multicentre clinical study to evaluate the efficacy and safety of rituximab in the first episode of paediatric idiopathic nephrotic syndrome.
Liu J; Shen Q; Xie L; Wang J; Li Y; Chen J; Fang X; Tang X; Qian B; Xu H
BMJ Open; 2022 Oct; 12(10):e064216. PubMed ID: 36223961
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.
Ravani P; Rossi R; Bonanni A; Quinn RR; Sica F; Bodria M; Pasini A; Montini G; Edefonti A; Belingheri M; De Giovanni D; Barbano G; Degl'Innocenti L; Scolari F; Murer L; Reiser J; Fornoni A; Ghiggeri GM
J Am Soc Nephrol; 2015 Sep; 26(9):2259-66. PubMed ID: 25592855
[TBL] [Abstract][Full Text] [Related]
20. Rituximab therapy for childhood onset idiopathic nephrotic syndrome: experience of a Portuguese tertiary center.
Gomes R; Mosca S; Bastos-Gomes M; Correia-Costa L; Rocha L; Teixeira A; Costa T; Sameiro-Faria M; Matos P; Mota C
J Bras Nefrol; 2023; 45(3):326-334. PubMed ID: 36259942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
